Chief of Immunotherapy and Rare Tumor Unit
IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" , Italy
Dr. Ridolfi Laura obtained her medical degree at the University of Bologna, the postgraduate specialization in Medical Oncology at the University of Ferrara and the doctorate in Immunology and cellular biology at the University of Turin. She has twenty years’ experience as Principal Investigator and Sub-Investigator of phase I-III International clinical trials and won a Grant from “Ricerca Finalizzata 2009- Ministero della Salute – Direzione Generale della Ricerca Scientifica e Tecnologica” on the treatment of melanoma and renal cell carcinoma with high dose IL2 plus radiotherapy. From jenuary 2018 is a member of the Ethics Commitee AVEN (Area Vasta Emilia Nord) and from october 2022 she is the medical director of the Somatic Cell therapy Unit in solid tumors and the Coordinator of the clinical and preclinical research in the field of rare tumors and the development of new cellular product at IRST “Dino Amadori”. She is a funding member of NOTA (Network Officine Terapie Avanzate APS) a no profit network of Italian authorized cell factories and regional coordinator of Women for Oncology-Italy.
